Apotex Pty Ltd v Warner-Lambert Company LLC (No 2)

Link copied
Case Copied 67 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238

File numbers: NSD 763 of 2013
NSD 251 of 2014
Judge: NICHOLAS J
Date of judgment: 21 October 2016
Catchwords: PATENTS – construction of patent specification describing methods for treating pain comprising administering a therapeutically effective amount of a compound to a mammal in need of said treatment – whether patent obtained by misrepresentation or false suggestion – whether misrepresentation or false suggestion made with respect to compound used in animal tests reported in complete specification – whether misrepresentation or false suggestion was a material inducing factor leading to grant of the patent – whether claims invalid and liable to be revoked on ground that the complete specification does not describe the invention fully – where complete specification does not include any reference to clinical trials involving humans – where complete specification refers only to experiments carried out on rats – whether complete specification provides notional skilled addressee with sufficient information to enable inventive method to be used in the treatment of humans – whether claims invalid and liable to be revoked on ground that the invention claimed is not useful – whether Swiss style claims infringed by importation and sale in Australia of a medicament made outside the patent area – meaning of “exploit” as defined in Schedule 1 of Patents Act 1990 (Cth)
Legislation:

Patents Act 1990 (Cth) ss 12, 13, 18(1), 22A, 40(2), (3), 120, 138(3), (4)

Patents Act 1952 (Cth) ss 70, 100(1)(k)

Patents Act 1949 (UK) s 32(l)(j)

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Evidence Act 1995 (Cth) s 136

Cases cited:

Advanced Building Systems Pty Ltd v Ramset Fasteners (Aust) Pty Ltd (1998) 194 CLR 171

Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 253 CLR 284

Aristocrat Technologies Australia Pty Ltd v Konami Australia Pty Ltd (2015) 114 IPR 28

AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324

Biogen Inc v Medeva Plc [1997] RPC 1

British Liquid Air Co Ltd v British Oxygen Company Ltd (1908) 25 RPC 577

Electric & Musical Industries Ltd v Lissen Ltd (1938) 56 RPC 23

Eli Lilly and Company v Pfizer Overseas Pharmaceuticals (2005) 64 IPR 506

Eli Lilly & Company v Janssen Alzheimer Immunotherapy [2014] RPC 1

Fawcett v Homan (1896) 13 RPC 398

Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd [2009] RPC 23

Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd (2001) 207 CLR 1

ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (1999) 45 IPR 577

Jupiters Ltd v Neurizon Pty Ltd (2005) 222 ALR 155

Lane Fox v Kensington and Knightsbridge Electric Lighting Co Ltd [1892] 3 Ch 424

Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 217 CLR 274

Merck & Co Inc v Arrow Pharmaceuticals Ltd (2006) 154 FCR 31

Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Ltd

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] FCA 1238
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) involved a dispute over the validity of a patent for a method of treating pain, held by Warner-Lambert Company LLC. Apotex challenged the patent's validity on multiple grounds, including misrepresentation or false suggestion in the specification, insufficiency, and lack of utility. The case also considered whether Swiss-style claims in the patent were infringed by the importation and sale of a medicament made outside the patent area. The court had to determine whether the patent specification provided enough information for a notional skilled addressee to replicate the invention, and whether the claims were invalid due to misrepresentation or false suggestion, insufficiency, or lack of utility.

The court addressed the validity challenges by first examining the specification's disclosure regarding animal tests and whether it included sufficient information for a notional skilled addressee to replicate the invention in humans. The court considered the relevant fields of expertise, including pharmacology, pharmaceutical formulation, pain medicine, and organic chemistry, and the common general knowledge available at the priority date. The court found that the specification, despite not including human clinical trials, provided enough information for the notional skilled addressee to replicate the invention. Regarding misrepresentation or false suggestion, the court concluded that no material misrepresentation or false suggestion was made with respect to the compound used in animal tests, and thus the patent was not invalid on this ground.

The court also considered whether the complete specification described the invention fully and whether the invention was useful. It found that the complete specification was sufficient, and the invention was useful as it provided a method for treating pain. Finally, the court addressed the issue of infringement under the Swiss-style claims, determining the meaning of "exploit" as defined in the Patents Act 1990 (Cth). The court found that the importation and sale of the medicament did not infringe the claims.

The court rejected all challenges to the validity of the patent claims and granted Warner-Lambert Company LLC quia timet injunctive relief against Apotex and GPPL for threatened infringement. The proceedings were relisted to make final orders, and the parties were directed to file and serve a draft minute of the final orders within 7 days. Certain parts of the reasons for judgment were ordered to be kept confidential.

Orders

Orders of the court

1. The applicants and cross-respondents file and serve a draft minute of the final orders they seek in this proceeding within 7 days.

2. The proceeding stand over to a date to be fixed for the purpose of making final orders.

3. Up to and including 28 October 2016 or further order, the contents of paragraphs [275] to [281] (inclusive) and [283] of the reasons for judgment of Nicholas J dated today be kept confidential and not be made available for public inspection.

4. There be liberty to apply on 24 hours’ notice.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

In the present case people with a practical interest in the invention the subject of the Patent would include pharmacologists, clinicians (pain specialists and other clinicians who treat pain), pharmaceutical formulators and organic chemists. Thus, the relevant fields of expertise include pharmacology, pharmaceutical formulation, pain medicine, and organic chemistry. SCIENTIFIC BACKGROUNDCommon general knowledge The notional skilled addressee will possess the common general knowledge in each of these fields in so far as they are relevant to the subject matter of the Patent. In the present case it will include the background knowledge and experience available to all those persons engaged in the particular fields that I have identified including publications to which they would refer as a matter of course: see Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Ltd (1980) 144 CLR 253 at 292 per Aickin J; ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (1999) 45 IPR 577 at [112] per Emmett J. There was no issue between the parties as to the state of the common general knowledge at the priority date. Some of the relevant scientific and medical knowledge referred to in the evidence was first acquired by the experts after the priority date (particularly in relation to “central sensitisation”) and the following account of the relevant science indicates if this is so. Subject to that qualification, the matters set out in this section of my reasons (which is mostly drawn from Professor Christie’s and Professor Easton’s affidavit evidence) were matters of common general knowledge as at the priority date. PainPain classification Pain is a complex phenomenon that reflects a blend of sensory, cognitive, emotional, and social components. It occurs in the context of fundamental biological events taking place at multiple levels of the “somatosensory system”. The somatosensory system is the part of the nervous system (including the brain) that conveys sensory stimuli, such as sensations of touch, pressure, temperature, proprioception (position) and vibration, arising from the muscles, joints, internal organs, skin and fascia to the brain where it is interpreted. Pain has been defined as “[a]n unpleasant sensory and emotional experience associated with actual and potential tissue damage, or described in terms of such damage” (see International Association for the Study of Pain (“IASP”), Classification of Chronic Pain, IASP Press, 2nd Edition, 1994 at p 210). Descriptions of the underlying biological mechanisms associated with pain are particularly relevant in the preclinical environment where an understanding of pain mechanisms is central to the research and the development of new pain therapies and drug indications. In the clinical setting there is limited availability of diagnostic tools to definitively identify the involvement or contribution of a biological mechanism in a patient presenting with pain and in this setting pain is usually categorised in other ways. Pain may be described in terms of its etiology (ie. the cause or set of causes of a disease or condition), pathology or disease-base (eg. osteoarthritis), duration (eg. acute or chronic), or by the location of the pain (eg. headache, lower back pain).

Evidence

Evidence Before The Court

In opening Apotex also contended that it did not threaten to infringe claims 31 and 32 “because there were no relevant methods of treatment exemplified in the Patent.” This contention was not developed by Apotex in its closing submissions. In any event, so far as claim 31 is concerned, the point is not open to Apotex on the pleadings. As to claim 32, it seems to reflect a particularly poor attempt by the patentee to draft what was probably intended to be a claim for the use of a relevant compound as a medicament for the treatment of pain. Since the examples and accompanying figures referred to in claim 32 shows the use of a relevant compound in experiments on rats, I do not think it can be said that Apotex threatens to infringe claim 32. RULINGS ON EVIDENCE I have already dealt with the relevance objection made by Pfizer based upon Apotex’s pleading at [171] to [185]. I admitted into evidence provisionally a bundle of copies of patent specifications (Ex 11) tendered by Apotex that relate to the use of various pharmaceutical compositions in the treatment of different medical conditions. These were said by Apotex to be relevant to the issue of sufficiency in that they revealed that other patentees included in their patent specification details of clinical trials in humans that were conducted prior to filing. In my view what other patentees may disclose in their patent specifications or at what point in their research and development they may choose to file for patent protection are not relevant to any fact in issue in these proceedings. Exhibit 11 is excluded from evidence on that basis. I also admitted into evidence provisionally the Beach Report on the basis that it may be relevant to the issue of utility. Although I have not derived any assistance from the Beach Report, I consider that it is relevant and it is admitted into evidence unconditionally. During the course of Professor Christie’s and Professor Easton’s cross-examinations Mr Bannon SC sought various orders pursuant to s 136 of the Evidence Act 1995 (Cth) on the basis that aspects of their evidence relating to the Carlton paper and the Jun paper might be unfairly prejudicial to Pfizer or misleading or confusing. Having considered their evidence in relation to those matters I am not satisfied that the requirements of s 136 have been satisfied. I therefore do not propose to make the orders sought. The parties agreed on various other exclusions and limitations in relation to the evidence that are recorded in the transcript and documents marked for identification. It is not necessary for me to say anything more about those agreed rulings. DISPOSITION The challenges to the validity of claims 1 to 32 are rejected. Pfizer is entitled to quia timet injunctive relief against Apotex for threatened infringement of claims 1 to 31 and against GPPL for threatened infringement of claims 1 to 30. Pfizer will be directed to file and serve a minute of the orders it seeks within 7 days. Both proceedings will be relisted on a date to be fixed for the purpose of making final orders.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.